Recent Updates
Recently added Catalysts
TARS Positive Sentiment Score: 70/100

Tarsus to Participate in Upcoming Investor Conferences

Thursday, February 26, 2026 2 min read
Key Takeaway: Tarsus Pharmaceuticals, Inc. has announced its participation in two upcoming investor conferences, highlighting its ongoing engagement with investors. The TD Cowen 46th Annual Health Care Conference is scheduled for March 3rd, followed by the Barclays 28th Annual Global Healthcare Conference on March 11th. The company continues to advance its pipeline, including FDA-approved treatments and investigational therapies targeting ocular and infectious diseases.

Market Sentiment Analysis

POSITIVE FACTORS

  • Tarsus Pharmaceuticals is participating in significant investor conferences, showcasing confidence and engagement with the investment community.
  • The company's pipeline addresses high unmet medical needs, particularly in eye care and infectious disease prevention.
  • Tarsus has FDA approval for XDEMVY, demonstrating regulatory progress and market validation.

Full Press Release Details

IRVINE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences:
TD Cowen 46th Annual Health Care Conference on Tuesday, March 3rd, at 11:30 a.m. PT / 2:30 p.m. ET.
Barclays 28th Annual Global Healthcare Conference on Wednesday, March 11th, at 9:30 a.m. PT / 12:30 p.m. ET.
Live webcasts and additional information can be accessed on the events section of the Tarsus website. Replays will be available on the Tarsus website within 48 hours and will be archived for a limited time.
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care and infectious disease prevention. XDEMVY® (lotilaner ophthalmic solution) 0.25% is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 as an ophthalmic gel for the potential treatment of ocular rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease, all of which are in Phase 2.
Sr. Director, Corporate Communications
Head of Investor Relations
DNakasone@tarsusrx.com

Frequently Asked Questions

What conferences will Tarsus Pharmaceuticals attend?

Tarsus will participate in the TD Cowen Health Care Conference on March 3 and the Barclays Global Healthcare Conference on March 11.

Where can I find more information about Tarsus events?

Additional details and live webcasts are available in the events section on the Tarsus website.

What is XDEMVY® used to treat?

XDEMVY® (lotilaner ophthalmic solution) 0.25% is FDA approved for treating Demodex blepharitis.

What diseases is Tarsus Pharmaceuticals addressing?

Tarsus focuses on high unmet needs in eye care and infectious disease prevention.

What is TP-04 being developed for?

TP-04 is an ophthalmic gel in Phase 2 for potential treatment of ocular rosacea.

Tags: TARS Viatris Investor Conferences Healthcare Tarsus Pharmaceuticals investor conferences FDA approved pipeline
Last updated: Feb 26, 2026